Frataxin depletion leads to decreased soma size and activation of AMPK metabolic pathway in dorsal root ganglia sensory neurons

This study demonstrates that frataxin depletion in dorsal root ganglia sensory neurons causes a reduction in soma size driven by mitochondrial dysfunction-induced AMPK hyperactivation and mTOR suppression, a phenotype that can be rescued by restoring frataxin, inhibiting AMPK, or treating with alpha-lipoic acid.

The Gist

The Big Picture: A Power Plant Failure in a Tiny City

Imagine your body is a giant city, and inside that city are billions of tiny workers called neurons (nerve cells). Some of these workers are like the city's "GPS system," telling your body where your limbs are and how to move. These are called proprioceptive neurons, and they live in a neighborhood called the Dorsal Root Ganglia (DRG).

In a disease called Friedreich's Ataxia (FA), these GPS workers start to fail. The paper investigates why they fail and how we might fix them.

The Culprit: The Broken Generator (Frataxin)

Every neuron has a tiny power plant inside it called a mitochondrion. To run this power plant, the cell needs a special fuel additive called Frataxin. Think of Frataxin as the spark plug or the oil filter for the engine.

In FA, the body doesn't make enough Frataxin. Without it:

1. The power plant (mitochondria) starts sputtering and producing less energy (ATP).
2. The engine starts overheating and creating toxic exhaust (oxidative stress).
3. The cell gets confused about how much "fuel" (iron) it has, leading to a mess.

The Discovery: The Workers Shrink Instead of Dying

Usually, when a power plant fails, the worker dies. But the researchers found something surprising: These neurons didn't die immediately. They stayed alive for weeks, even with a broken engine.

However, they did something strange: They shrunk.

Imagine a construction worker who is supposed to build a massive skyscraper. Because the power is out and the tools are broken, the worker doesn't quit; instead, they decide to build a tiny, sad shed instead. The neurons stopped growing to their full size. Their "bodies" (called the soma) became much smaller than normal.

The Mechanism: The "Energy Saver" Switch Got Stuck

Why did they shrink? The researchers found the culprit: a master switch inside the cell called AMPK.

• The Analogy: Think of AMPK as the cell's "Eco-Mode" button. When a house runs out of electricity, you flip the switch to Eco-Mode to save what little power you have left. You turn off the lights, the heater, and the TV.
• What went wrong: In these FA neurons, the power plant was failing so badly that the cell thought, "We are starving for energy! We need to save everything!" So, it flipped the Eco-Mode switch (AMPK) and stuck it in the "ON" position.
• The Result: Because the switch was stuck, the cell shut down its "construction projects" (growth). It stopped building the big skyscraper (the neuron) and settled for the tiny shed.

The researchers also found that another switch, called mTOR (the "Growth Button"), was turned off because the Eco-Mode switch (AMPK) was pushing it down.

The Solution: A Magic Antioxidant (Alpha-Lipoic Acid)

The team tried to fix this. They knew that if they could just give the neurons more Frataxin, they would get better. But since we can't easily give them the missing protein, they tried a different approach: Alpha-Lipoic Acid (ALA).

Think of ALA as a super-charged battery charger and a fire extinguisher rolled into one.

1. The Fire Extinguisher: It soaks up the toxic exhaust (oxidative stress) that was damaging the cell.
2. The Battery Charger: It helps the mitochondria make a little more energy.

The Result: When the researchers added ALA to the shrinking neurons, something amazing happened. The "Eco-Mode" switch (AMPK) finally turned OFF. The "Growth Button" (mTOR) turned back ON. The neurons stopped being tiny sheds and started growing back into skyscrapers.

Why This Matters

1. It's not just about death: This paper shows that in FA, the problem isn't just that neurons die; it's that they stop developing properly and shrink. This explains why patients have trouble with movement and sensation.
2. A New Path to Treatment: Instead of just trying to replace the missing Frataxin (which is hard), this study suggests we can treat the symptoms of the broken engine. By using drugs like ALA (or future drugs that target the AMPK switch), we might be able to stop the neurons from shrinking and help them grow back, even if the engine is still a bit broken.
3. A New Test Lab: The scientists built a special "test kitchen" (a cell culture model) where they can grow these neurons in a dish. This makes it much easier to test thousands of different medicines quickly to see which ones work best.

The Bottom Line

Friedreich's Ataxia causes neurons to lose their power, which tricks them into thinking they are starving. This makes them shrink instead of grow. The researchers found that a common supplement called Alpha-Lipoic Acid can trick the cell back into "growth mode" by cleaning up the toxic exhaust and boosting energy, potentially offering a new way to treat the disease.

Technical Summary

1. The Problem

Friedreich's Ataxia (FA) is a progressive neurodegenerative disorder caused by a deficiency in the mitochondrial protein frataxin (FXN). This deficiency leads to impaired iron-sulfur (Fe-S) cluster biogenesis, mitochondrial dysfunction, and oxidative stress.

• Clinical Gap: The hallmark of FA is the degeneration of large proprioceptive neurons in the Dorsal Root Ganglia (DRG). However, the mechanisms driving the selective vulnerability of these neurons remain unclear.
• Model Limitations: Existing cellular models (e.g., iPSC-derived neurons or partial knockdowns) often exhibit modest, variable phenotypes that are difficult to scale for mechanistic dissection or high-throughput screening. There is a need for a robust model that recapitulates the severe biochemical and morphological defects of FA in sensory neurons to identify therapeutic targets.

2. Methodology

The authors developed a novel, scalable primary culture model of embryonic mouse DRG sensory neurons with complete frataxin depletion.

• Model System: DRGs were harvested from E13.5 embryos carrying a conditional Fxn allele (Fxn^L3/L3).
• Genetic Manipulation: Neurons were infected with AAV9-CreGFP to excise exon 4 of the Fxn gene, resulting in near-complete FXN depletion (Knockout/KO). Control (CT) neurons were infected with an empty AAV9 vector.
• Culture Conditions: Cultures were treated with antimitotics (Uridine/FUdR) to remove glial cells, ensuring a highly enriched neuronal population.
• Interventions:
  • Rescue Experiments: Re-expression of human FXN (hFXN) via AAV9.
  • Metabolic Rescue: Treatment with $\alpha$-Lipoic Acid (ALA) or expression of bacterial mitochondrial Lipoate Ligase A (mtLplA) to bypass the lipoylation defect.
  • Pathway Modulation: Pharmacological activation/inhibition of AMPK (AICAR, Compound 991, Rapamycin) and genetic inhibition of AMPK using a dominant-negative mutant (AMPK$\alpha$-K56R).
• Assays: The study utilized Western blotting, enzymatic activity assays (SDH, PDH, LDH), Seahorse XF analysis (mitochondrial respiration), high-content imaging (soma size, ROS, mitochondrial iron), and RT-qPCR.

3. Key Contributions

• Novel Phenotype Identification: The study identifies a specific, quantifiable defect in neuronal soma size (hypoplasia) in frataxin-deficient neurons, distinct from immediate cell death.
• Mechanistic Link: It establishes a direct causal link between mitochondrial dysfunction, AMPK hyperactivation, mTOR inhibition, and the resulting impairment in neuronal growth.
• Therapeutic Insight: It demonstrates that $\alpha$-Lipoic Acid (ALA) can rescue the growth defect not just by restoring lipoylation, but by correcting bioenergetics (ATP levels) and oxidative stress, thereby normalizing AMPK signaling.
• Scalable Platform: The model provides a robust, high-throughput compatible system for screening compounds that target downstream metabolic pathways in FA.

4. Key Results

A. Recapitulation of FA Biochemical Hallmarks

The KO model successfully reproduced key FA features:

• Fe-S Deficiency: Significant reduction in Succinate Dehydrogenase (SDH) activity and instability of Fe-S cluster proteins.
• Mitochondrial Dysfunction: Reduced basal respiration and respiratory capacity (Seahorse), increased mitochondrial mass (compensatory), and giant mitochondria with collapsed cristae (EM).
• Iron & ROS Dysregulation: Activation of the Iron Regulatory Protein 1 (IRP1) pathway (increased TFR1, decreased Ferritin) and elevated mitochondrial oxidative stress (MitoSOX), particularly at later time points (21–30 days in vitro).
• Viability: Despite severe dysfunction, neurons remained viable for weeks, suggesting a developmental/growth arrest rather than acute necrosis.

B. The Soma Size Defect

• Phenotype: While cell survival was unchanged, KO neurons exhibited a significant reduction in soma size (1.3-fold smaller at 21 days, 1.5-fold at 30 days) compared to controls.
• Rescue: Re-expression of FXN restored soma size in a dose-dependent manner, confirming the phenotype is directly linked to FXN levels.

C. Impaired Lipoylation and Metabolic Consequences

• Lipoylation Defect: FXN depletion reduced the activity of Lipoic Acid Synthase (LIAS), leading to hypolipoylation of Pyruvate Dehydrogenase (PDH) and $\alpha$-Ketoglutarate Dehydrogenase (KGDH).
• Metabolic Accumulation: This resulted in reduced PDH activity and elevated levels of Glycine and Branched-Chain Amino Acids (BCAAs).
• Partial Rescue: Expressing bacterial mtLplA restored lipoylation and PDH activity but failed to rescue the soma size defect. However, high-dose ALA supplementation fully rescued the soma size, suggesting ALA acts via mechanisms beyond simple lipoylation (likely antioxidant and bioenergetic).

D. The AMPK-mTOR Axis as the Driver

• AMPK Activation: KO neurons showed a 1.7-fold increase in phosphorylated AMPK$\alpha$ (Thr172) and downstream targets (ACC, ULK1, Raptor).
• mTOR Inhibition: Concurrently, mTOR signaling was suppressed (increased p-Raptor, decreased p-P70S6K).
• Causality:
  • Pharmacological activation of AMPK or inhibition of mTOR in control neurons mimicked the soma size reduction.
  • Genetic inhibition of AMPK (using AMPK$\alpha$-K56R) in KO neurons fully restored soma size to control levels.
• Conclusion: The growth defect is driven by metabolic stress (low ATP/high ROS) activating AMPK, which inhibits the anabolic mTOR pathway.

E. Mechanism of ALA Rescue

Treatment with ALA:

1. Reduced mitochondrial oxidative stress.
2. Restored intracellular ATP levels.
3. Normalized AMPK activation (reduced p-AMPK and p-ULK1).
4. Rescued soma size.
   This indicates ALA works by improving the bioenergetic/redox balance, thereby deactivating the stress-induced AMPK pathway.

5. Significance

• Pathophysiological Insight: The study shifts the focus from purely neurodegenerative cell death to developmental impairment (failure of soma growth/maturation) in FA. It suggests that the hypoplasia observed in FA patients may be a direct consequence of metabolic signaling dysregulation during neuron maturation.
• Therapeutic Strategy: It identifies the AMPK-mTOR axis as a critical therapeutic target. Instead of solely focusing on replacing frataxin, modulating downstream metabolic signaling (e.g., inhibiting AMPK or activating mTOR) could restore neuronal growth.
• Drug Repurposing: The findings support the potential of $\alpha$-Lipoic Acid (or similar antioxidants/bioenergetic enhancers) as a therapeutic agent to mitigate neuronal growth defects in FA by correcting the metabolic stress response.
• Model Utility: The established primary DRG culture model is a powerful tool for future high-throughput drug screening aimed at rescuing neuronal morphology and metabolic homeostasis in FA.